|
|
CAF-09 |
|
Vaxjo ID |
152 |
|
Vaccine Adjuvant Name |
CAF-09 |
|
Adjuvant VO ID |
VO_0005473
|
|
Description |
A vaccine adjuvant that is a lipid-based vaccine adjuvent based on cationic surfactant dimethyl-dioctadecyl ammonium (DDA) combined with C-type lectin agonist monomycoloyl glycerol (MMG) and TLR3 agonist poly I:C. CAF09b is able to induce CD8+ T-cell response |
|
Stage of Development |
Clinical Trial |
|
Location Licensed |
Denmark (Staten Serum Institute) |
|
Components |
cationic surfactant dimethyl-dioctadecyl ammonium (DDA) combined with C-type lectin agonist monomycoloyl glycerol (MMG) and TLR3 agonist poly I:C |
|
Preparation |
liposomes prepared using thin film method; 1.08 mL of tris buffer added to ampule and mixed with 0.12 mL of NPV-dp001, 1 mL of that added to 1.0mL of CAF09b (2500/500/125) |
|
Function |
increase uptake of peptides by APCs and promote their activation status to induce cross-presentation and proinflammatory signaling |
| References |
Mørk et al., 2022: Mørk SK, Kadivar M, Bol KF, Draghi A, Westergaard MCW, Skadborg SK, Overgaard N, Sørensen AB, Rasmussen IS, Andreasen LV, Yde CW, Trolle T, Garde C, Friis-Nielsen J, Nørgaard N, Christensen D, Kringelum JV, Donia M, Hadrup SR, Svane IM. Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF®09b, in patients with metastatic melanoma. Oncoimmunology. 2022; 11(1); 2023255. [PubMed: 35036074].
Zimmermann et al., 2022: Zimmermann J, Schmidt ST, Trebbien R, Cox RJ, Zhou F, Follmann F, Pedersen GK, Christensen D. A Novel Prophylaxis Strategy Using Liposomal Vaccine Adjuvant CAF09b Protects against Influenza Virus Disease. International journal of molecular sciences. 2022; 23(3); . [PubMed: 35163772].
|
|
